Effect of Memantine on epileptic patients
Phase 3
- Conditions
- Epilepsy.Epilepsy and recurrent seizures
- Registration Number
- IRCT20121110011424N5
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients between 15-65 years old
Epileptic patients who received anti epileptic drugs over 6 months with mild to moderate cognition impairment
Seizure episodes less than four times a month
Exclusion Criteria
Progressive neurologic disease, psychiatric disorders, and mental retardation
Severe medical illnesses such as renal failure
Pregnancy or breast feeding
Patients during inter-ictal phase (2 weeks)
Patients with seizure episodes more than four times a month
adverse drug effect
drug allergy or intolerance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive status score according to MMSE (Folstein mini-mental state examination) criteria. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of MMSE (Folstein mini-mental state examination ).;Cognitive status score according to FAB (Frontal Assessment Battery). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of FAB (Frontal Assessment Battery).;Cognitive status score according to MoCA (Montreal Cognitive Assessment). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of MoCA (Montreal Cognitive Assessment).;Adverse events. Timepoint: 16 weeks after intervention. Method of measurement: Adverse events form.
- Secondary Outcome Measures
Name Time Method